VYNE Therapeutics Inc.

NasdaqCM:VYNE Stock Report

Market Cap: US$21.2m

VYNE Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VYNE?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders711,3842.13%
Hedge Funds2,000,0006%
Institutions12,330,67337%
General Public18,281,11454.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100%.

Top Shareholders

Top 25 shareholders own 44.04% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6%
Nantahala Capital Management, LLC
2,000,000US$1.3m100%0.07%
4.89%
Lynx1 Capital Management LP
1,628,700US$1.0m0%0.14%
4.83%
Shay Capital LLC
1,610,242US$1.0m-0.87%0.12%
3.73%
Anson Group
1,243,106US$789.9k-2.45%0.08%
3.35%
Access Industries, Inc.
1,116,586US$709.5k0%0.01%
3.19%
ADAR1 Capital Management, LLC
1,063,899US$676.0k319%0.04%
2.84%
T3 Trading Group, LLC
945,000US$600.5k0%0.62%
2.75%
Braidwell LP
916,077US$582.1k0%0.02%
1.54%
Citadel Advisors LLC
514,443US$326.9k1,590%no data
1.5%
Kvp Capital Advisors, LP
500,551US$318.0k0%0.27%
1.32%
David Domzalski
438,779US$278.8k9.16%no data
1.28%
Two Sigma Investments, LP
426,412US$270.9k93.8%no data
1.15%
Acadian Asset Management LLC
381,797US$242.6k-40.2%no data
0.97%
Geode Capital Management, LLC
322,711US$205.1k43.3%no data
0.79%
Ikarian Capital, LLC
264,912US$168.3k0%0.03%
0.79%
Vanguard Capital Management, LLC
264,557US$168.1k0%no data
0.55%
Vanguard Fiduciary Trust Company
183,443US$116.6k0%no data
0.54%
UBS Asset Management AG
179,784US$114.2k186%no data
0.48%
XTX Markets Limited
158,396US$100.6k100%no data
0.35%
Rangeley Capital, LLC
118,064US$75.0k18.1%0.07%
0.3%
Tyler Zeronda
99,788US$63.4k-3.86%no data
0.29%
Jane Street Group, LLC
95,645US$60.8k32.2%no data
0.24%
Boothbay Fund Management, LLC
81,371US$51.7k0%no data
0.19%
Iain Stuart
62,857US$39.9k-44.1%no data
0.17%
Susquehanna International Group, LLP
57,784US$36.7k-42.4%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/22 08:49
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VYNE Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas TsaoBarclays
Jason Matthew GerberryBofA Global Research
Louise ChenGuggenheim Securities, LLC